COMP <GO>
ESYN vs HKPD // DIVIDEND YIELD & FCF PAYOUT SAFETY
EnerSyn Global Inc. (NASDAQ) VS. Cellyan Biotechnology Co. Ltd (Class A) (NASDAQ) • 15-METRIC TALLY: ESYN 2
— HKPD 0
■ METRIC PARITY
LAST: $1.83 (+3.10%) • MKT CAP: $54.4M
dividend-safety
0.00%
LAST: $2.19 (+0.46%) • MKT CAP: $5.4M
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ESYN VS. HKPD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ESYN | HKPD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 53.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.25% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -30.80% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.6 | 35.5 | +7.07 | ESYN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $54.4M | $5.4M | $49.0M | ESYN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ESYN REV | HKPD REV | ESYN GROSS % | HKPD GROSS % | ESYN FCF | HKPD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $866.9K | — | 53.0% | — | -$1.8M | — |
| FY 2024 | $1.3M | — | 48.0% | — | -$1.8M | — |
| FY 2023 | $1.2K | — | — | — | -$2.6M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ESYN // BETA —
HKPD // BETA —